Evolent Health (EVH) Fundamental Analysis: Revenue, Earnings & Valuation

1.02 / 10

Underperform

Fundamental rating is Underperform with a 1/10 quality score. Key metrics like ROE (-81.8%) and annualized ROE are negative, Asset‑MV and net‑asset growth are poor, while cash‑to‑market is relatively strong but insufficient to offset weaknesses.

Analysis Checks(5/10)

Net assets per share (growth rate compared to beginning of year %)

Value-57.27

Score0/3

Weight24.53%

1M Return-6.98%

Annualized return on equity (%)

Value-81.81

Score3/3

Weight-3.58%

1M Return0.85%

Quick ratio

Value2.28

Score0/3

Weight13.68%

1M Return-3.43%

Fixed assets turnover ratio

Value22.82

Score1/3

Weight10.75%

1M Return-2.80%

Long-term debt to working capital ratio (%)

Value9.07

Score2/3

Weight12.11%

1M Return-3.64%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight11.64%

1M Return-3.03%

Asset-MV

Value-0.49

Score0/3

Weight20.10%

1M Return-5.93%

ROE (%)

Value-81.81

Score3/3

Weight-3.58%

1M Return0.85%

Current assets / Total assets (%)

Value26.66

Score0/3

Weight21.88%

1M Return-5.96%

Cash-MV

Value1.02

Score3/3

Weight-7.54%

1M Return1.72%

Is EVH undervalued or overvalued?

EVH scores 1.02/10 on fundamentals and holds a Premium valuation at present. Backed by its -72.13% ROE, -28.49% net margin, -0.43 P/E ratio, 0.60 P/B ratio, and -525.93% earnings growth, these metrics solidify its Underperform investment rating.